StockNoteStockNote
S.P.M Joint Stock Company (SPM), formerly known as Do Thanh Pharmaceutical Company, was established in 1988. In 2007, the company transformed its operating model into a joint-stock company. The main business activities of the Company are: Production and purchase of cosmetics and foodstuffs; Production and purchase of pharmaceuticals; Rental services of premises, offices... The company's main products include: MyVita Multivitamin, MyVita C75 Lemon, MyVita C75 Orange, Biseptol, Helinzole, Septidas, Enpovid AD, Dailyvit, Devomir, Maxgel... In which MyVita Multi is the best-selling product for the vitamin and mineral product group. SPM's products have been available in a number of countries and are trusted by customers such as the US, Myanmar, Malaysia, Laos, Singapore, Cambodia,... In the coming year, besides investing and strengthening the Asian market, SPM will accelerate its market expansion to Europe and Africa. On May 21, 2010, SPM officially traded at the Ho Chi Minh Stock Exchange (hose).
SPM currently has a market capitalization of roughly VND 117 billion, placing it in the small-cap group on the Vietnamese stock market. Its current P/E of 20,3x is 34% above its own 7-year average (15,2x), suggesting the stock is trading richer than its historical norm. P/B stands at 0,1x, 35% below its multi-year average of 0,2x. Return on equity (ROE) is at -0,7%, down from -0,2% the year before. Its debt-to-equity ratio of 0,1x is low, reflecting a conservative capital structure. In 2025, revenue fell 15% year-on-year while after-tax profit fell 137%.
This note is generated automatically from the stock's real financial data, for reference only — not investment advice.
Unit: VND billion. Growth (%) vs. previous period.
Unit: VND billion. Year-end values; current year uses latest session.
Unit: x. Financial debt over shareholders' equity.
Data aggregated from cafef.vn and VNDirect, for reference only, not investment advice.